{
    "clinical_study": {
        "@rank": "28536", 
        "arm_group": [
            {
                "arm_group_label": "AML 5mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 5 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "AML 10mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 10 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "CC 8mg", 
                "arm_group_type": "Experimental", 
                "description": "Candesartan Cilexetil 8 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "CC 16mg", 
                "arm_group_type": "Experimental", 
                "description": "Candesartan Cilexetil 16 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "AML 5mg/CC 8mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "AML 5mg/CC16mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "AML 10mg/CC 8mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks"
            }, 
            {
                "arm_group_label": "AML 10mg/CC 16mg", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the optimal dose of fixed-dose combination of\n      candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the\n      combination therapy compared to each of the monotherapy in patients with essential\n      hypertension."
        }, 
        "brief_title": "A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female aged \u2265 19 and \u2264 75 years old\n\n          -  Subject with mild-to-moderate uncomplicated essential hypertension\n\n          -  Subject who have voluntarily agreed to participate in the trial and signed the\n             written informed consent form, after having listened to the purpose, method, and\n             effect of the clinical trial\n\n        Exclusion Criteria:\n\n          -  Subject with severe hypertension (siDBP \u2265 115 mmHg or siSBP \u2265 185 mmHg)\n\n          -  Subject with difference in the mean blood pressure of over 10mmHg for siDBP  or\n             20mmHg for siSBP between both arms at the screening visit\n\n          -  Subject with known or suspected secondary hypertension [including but not limited to\n             any of the following: renovascular hypertension, adrenal medullary and cortical\n             hyperfunction, coarctation of the aorta, primary hyperaldosteronism, unilateral or\n             bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic\n             kidney disease, etc.]\n\n          -  Subject with symptomatic orthostatic hypotension (a sudden fall in siDBP of at least\n             10 mmHg or siSBP of at least 20 mmHg after standing compared with blood pressure from\n             the sitting or supine position)\n\n          -  Subject with Type 1 diabetes mellitus OR Type 2 diabetes mellitus with poor glucose\n             control (defined as subject on insulin treatment, with HbA1c > 9.0%, or with a\n             modification in the oral anti-hyperglycemic medication regiment within  the past 12\n             weeks prior to Visit 1)\n\n          -  Subject with severe heart disease (Congestive heart failure (NYHA Class III-IV),\n             ischemic heart disease within the past 6 months (unstable angina, myocardial\n             infarction), peripheral vascular disease, history of Percutaneous Transluminal\n             Coronary Angioplasty or Coronary Artery Bypass Grafting)\n\n          -  Subject with clinically significant ventricular tachycardia, atrial fibrillation,\n             atrial flutter or other clinically significant arrhythmia\n\n          -  Subject with hypertrophic obstructive cardiomyopathy, severe obstructive coronary\n             artery disease, aortic stenosis, haemodynamically relevant stenosis of the aortic or\n             mitral valve\n\n          -  Subject with severe cerebrovascular disease (history of stroke, cerebral infarction,\n             or cerebral hemorrhage within the past 6 months)\n\n          -  Subject with or with a history of wasting disease, autoimmune diseases (rheumatoid\n             arthritis, systemic lupus erythematosus), or connective tissue disease\n\n          -  Subject with known moderate or malignant retinopathy (history of retinal signs of\n             hemorrhage, visual impairment, retinal microaneurysm, etc. within the past 6 months)\n\n          -  Subject with the following clinically significant laboratory abnormalities:\n\n               -  AST or ALT > 3 x Upper Limit Normal (ULN)\n\n               -  Serum Creatinine > 1.5 ULN\n\n               -  Serum potassium < 3.5 mmol/L or > 5.5 mmol/L\n\n          -  Subject with any surgical or medical condition of the gastrointestinal tract that\n             might significantly alter the absorption, distribution, metabolism or excretion of\n             the drug\n\n          -  Subject with a history of malignant tumors including leukemia and lymphoma within the\n             past 5 years (except for localized basal cell carcinoma of the skin)\n\n          -  Subject with any chronic inflammatory condition needing chronic anti-inflammatory\n             therapy\n\n          -  Subject with chronic kidney disease on dialysis\n\n          -  Subject with cardiogenic shock\n\n          -  Subject requiring concomitant use of other antihypertensive or contraindicated drugs\n             during the entire study period\n\n          -  Subject with known or suspected contraindications, including history of allergy or\n             hypersensitivity to ARB or dihydropyridine derivatives\n\n          -  Subject who have previously experienced symptoms characteristic of angioedema during\n             treatment with ACE inhibitors or ARB\n\n          -  Pregnant women, lactating mothers, women suspected of being pregnant, women who wish\n             to be pregnant during the study, or women of child-bearing potential who are not\n             using medically acceptable methods of contraception (oral contraceptive,\n             intra-uterine device, condom, etc.), except for women with surgical sterilization.\n             Pre-menopausal women who are not surgically sterilized must have a negative pregnancy\n             test result at Visit 1 and maintain acceptable methods of contraception throughout\n             the study. Periodic abstinence (eg, symptothermal, calendar, post-ovulation methods),\n             or hormonal contraceptive are not acceptable methods of contraception\n\n          -  History of drug or alcohol abuse within the past 1 year\n\n          -  Use of other investigational products within the past 4 weeks\n\n          -  Subject who are judged unsuitable to participate in the study in the opinion of the\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "384", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059616", 
            "org_study_id": "CJ_CCA_201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AML 5mg", 
                    "AML 5mg/CC 8mg", 
                    "AML 5mg/CC16mg"
                ], 
                "description": "Daily oral administration for 8 weeks", 
                "intervention_name": "Amlodipine 5mg", 
                "intervention_type": "Drug", 
                "other_name": "Norvasc 5mg"
            }, 
            {
                "arm_group_label": [
                    "AML 10mg", 
                    "AML 10mg/CC 8mg", 
                    "AML 10mg/CC 16mg"
                ], 
                "description": "Daily oral administration for 8 weeks", 
                "intervention_name": "Amlodipine 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Norvasc 10mg"
            }, 
            {
                "arm_group_label": [
                    "CC 8mg", 
                    "AML 5mg/CC 8mg", 
                    "AML 10mg/CC 8mg"
                ], 
                "description": "Daily oral administration for 8 weeks", 
                "intervention_name": "Candesartan Cilexetil 8mg", 
                "intervention_type": "Drug", 
                "other_name": "Atacand 8mg"
            }, 
            {
                "arm_group_label": [
                    "CC 16mg", 
                    "AML 5mg/CC16mg", 
                    "AML 10mg/CC 16mg"
                ], 
                "description": "Daily oral administration for 8 weeks", 
                "intervention_name": "Candesartan cilexetil 16mg", 
                "intervention_type": "Drug", 
                "other_name": "Atacand 16mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Candesartan cilexetil", 
                "Candesartan", 
                "Antihypertensive Agents", 
                "Amlodipine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bundang", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul National University Bundang Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Dong-A University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yeungnam University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Konyang University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Chonnam National University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ilsan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inje University Ilsan Paik Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inha University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyungki-do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Hallym University Sacred Heart hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Pusan National University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Inje University Haeundae Baik Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Guro Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ewha Womans University Mokdong Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Yonsei University Gangnam Severance Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Severance Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul St. Mary's hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Soonchunhyang University Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ajou University Hospital"
                }, 
                "investigator": {
                    "last_name": "Seung-Jea Tahk", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wonju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Wonju Severance Christian Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Randomized, Double-blind, Multi-center, Phase\u2161 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension", 
        "overall_contact": {
            "email": "kssong1212@cj.net", 
            "last_name": "Geun Seog Song, PhD", 
            "phone": "82-2-6740-2440"
        }, 
        "overall_contact_backup": {
            "email": "keunji@cj.net", 
            "last_name": "Eun Ji Kim", 
            "phone": "82-2-6740-2443"
        }, 
        "overall_official": {
            "affiliation": "Ajou University School of Medicine", 
            "last_name": "Seung-Jea Tahk", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059616"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8", 
                "safety_issue": "No", 
                "time_frame": "Week 4 and 8"
            }, 
            {
                "measure": "Change in siDBP at week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Proportion of patients achieving \u0394siDBP > 10 mmHg and \u0394siSBP < 20 mmHg after 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }
        ], 
        "source": "CJ HealthCare Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CJ HealthCare Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}